AN EXCEPTIONALLY COST EFFECTIVE SERVICE INCLUDING FORMATS TO MEET EVERY INFORMATION NEED
Espicom's Breast Cancer Drug Futures includes formats to meet differing information requirement of customers. For constant vigilance and up-to-date coverage of lung cancer drug development users can access the 24/7 daily updated web service. For strategic periodic reviews we also provide quarterly-updated reports of all drugs in a convenient pdf document.
24/7 web access
Quarterly updated pdf reports
Single cost-effective price
All updates including any new drugs added during your license period
Related news
Espicom’s research methodology for forecasting and including an explanation of the competitor ratio analysis scoring system.
Globally, breast cancer is the second most common cancer after lung cancer....
....and the most common cancer for women. It is the second most common cause of death from cancer in women after lung cancer.
The breast cancer market is a steadily growing market due to effective treatments which have decreased mortality and resulted in a longer duration of therapy. The five-year survival rates for women with breast cancer have increased from under 70% 50 years ago to around 90% now.
Approximately 47% of breast cancer sales were derived from the US, with 41% Europe and 12% in Japan. Over the next six years Espicom forecasts that novel therapies including targeted monoclonal antibodies and small-molecule inhibitors, will increasingly be used in combination with chemotherapy and hormonal therapy.
NOW YOU CAN STAY IN TOUCH WITH THE DEVELOPMENTS WHICH MATTER
This all new web service from Espicom, Breast Cancer Drug Futures, assesses the future prospects for market success for individual drugs. Based on independent research and proprietary analysis, each product assessed brings the prospects for a product into clear focus. Best of all, each drug is regularly reviewed ensuring that latest developments are incorporated for you to see.
WITH EACH KEY DRUG ANALYSED IN THIS SERVICE YOU CAN...
Track the drug’s progress and stay in-touch with developments
Understand the drug’s novelty and mode of action
Evaluate the strength of the company developing/producing the drug
Review opportunities and challenges with Espicom’s unique 5-point competitive assessment
Know the launch timeframe for new products or indications
Be aware of promising mid-stage development candidates
Estimate future revenues with original 5-year forecasts for launched and leading pipeline candidates
Review significant clinical trial results
STRUCTURED ANALYSIS OF KEY DRIVERS AND DAMPENERS OF SUCCESS
For each product analysed there is an extensive and standardised review of the factors which can affect its clinical and commercial performance. Those factors include…
Novelty/rationale for mechanism of action
Current status
Proof of concept/clinical data
Development risks
Company expertise
Competition within the market-place
Sales forecast (for key late-stage and launched products)
Competitor ratio analysis score
Clinical trial results
OVER 65 CURRENT PROJECTS COVERED:
Because this service is continually updated, products will be added, deleted or enhanced in response to ongoing developments throughout the course of your licence. From time-to-time drug profiles may be removed from the service for essential updating.
Approved
Anastrozole
Bevacizumab
BIIB021
Capecitabine
Docetaxel
Doxorubicin
Fulvestrant
Gemcitabine
Goserelin
Ixabepilone
Lapatinib
Letrozole
Paclitaxel
Pazopanib
Saracatinib
Tamoxifen
Tegafur+gimeracil+oteracil
Tegafur+uracil
Phase III
Erbulin
Everolimus
Pertuzumab
Ramucirumab
Trabectedin
Vadimezan
Phase II/III
Pazopanib
Phase II
AE37
Axitinib
Bavituximab
Cixutumumab
E75 GM-CSF adjuvant vaccine
Figitumumab
Gimatecan
Linifanib
Motesanib diphosphate
NOV-002
Olaparib
Pemetrexed disodium
Retaspimycin
Sorafenib
SU14813
TSU-68
YM155
Phase I/II
AUY922
BIIB021
IMP321
MVA-BN-HER2
Tivozanib
Phase I
Adecatumumab
Brivanib
PTC299
Withdrawn
Saracatinib
Sagopilone
Sunitinib malate
Development Discontinued
ABT-751
CLEAR, CONCISE, AND ORIGINAL ANALYSIS GIVES YOU KEY PRODUCT INSIGHTS
Espicom's Cancer Drug Futures incorporate the latest analysis from our in-house team of life scientists and statisticians across a range of cancer areas. Their research builds upon Espicom's established knowledge base of up-to-date intelligence on thousands of pharmaceutical manufacturers and research companies, backed up by a fifteen years’ of archive material.
Taking all aspects of the market into account, from clinical trials, deals and alliances to company financial performance and drug sales, the analysis and forecasting that contributes to Espicom's Cancer Drug Futures is standardised across each individual launched product or drug candidate and is founded upon a diligent and thorough research process.
With Espicom’s Cancer Drug Futures you can easily evaluate the prospects of the drugs of interest to you and discover its progress in each indication. Each report provides individual and highly-detailed analysis of the drug, looking at the key factors affecting its future performance in the marketplace.
BUILD YOUR OWN DRUG FUTURES LIBRARY WITH 4D RESEARCH!
4D Research is Espicom’s tailored information service. Using 4D Research, customers can build their own Futures library of individual drugs of interest. Indeed, the service can include any of Espicom’s leading information services. Attractive discounts are available to buyers of multiple Futures and our cost-effective distribution license means these key data can be shared with colleagues.
Biotechnology Industry
Table of Contents
OVERVIEW .... 1
ADECATUMUMAB .... 4
Mode of Action .. 4
Current Status ... 4
Proof of Concept/Clinical Data ... 4
Development Risks . 5
Company Expertise . 5
Competition within the Market-place 5
Clinical Trial Results .... 5
GDC-0941 8
Mode of Action .. 8
Current Status ... 8
Company Expertise . 8
BRIVANIB 9
Mode of Action .. 9
Current Status ... 9
Proof of Concept/Clinical Data ... 9
Development Risks . 9
Company Expertise 10
Competition within the Market-place ....10
Competitor Ratio Analysis ....11
Forecast ...11
PTC299 . 13
Mode of Action 13
Current Status .13
Proof of Concept/Clinical Data .13
Development Risks 14
Company Expertise 14
AUY922 . 15
Mode of Action 15
Current Status .15
Proof of Concept/Clinical Data .16
Development Risks 16
Company Expertise 16
Competition within the Market-place ....16
Competitor Ratio Analysis ....16
BIIB021 . 18
Mode of Action 18
Current Status .18
Proof of Concept/Clinical Data .18
Development Risks 18
Company Expertise 18
Competition within the Market-place ....18
Competitor Ratio Analysis ....19
DASATINIB .. 20
Mode of Action 20
Current Status .20
Proof of Concept/Clinical Data .20
Development Risks 21
Company Expertise 21
Competition within the Market-place ....22
Competitor Ratio Analysis ....22
Forecast ...22
Clinical Trial Results ....23
Chronic Myelogenous Leukaemia .... 23
IMP321 .. 26
Mode of Action 26
Current Status .26
Proof of Concept/Clinical Data .26
Company Expertise 27
Competition within the Market-place ....27
Competitor Ratio Analysis ....27
ISPINESIB ... 28
Mode of Action 28
Current Status .28
Clinical Trial Results ..28
MVA-BN-HER2 .. 29
Mode of Action 29
Current Status .29
Proof of Concept/Clinical Data .29
Development Risks 29
Company Expertise 29
Competition within the Market-place ....30
Competitor Ratio Analysis ....30
TIVOZANIB .. 31
Mode of Action 31
Current Status .31
Proof of Concept/Clinical Data .31
Development Risks 32
Company Expertise 32
Competition within the Market-place ....33
Competitor Ratio Analysis ....33
Forecast ...33
AE37 ..... 35
Mode of Action 35
Current Status .35
Proof of Concept/Clinical Data .35
Development Risks 36
Company Expertise 36
Competition within the Market-place ....36
Competitor Ratio Analysis ....36
AXITINIB 37
Mode of Action 37
Current Status .37
Proof of Concept/Clinical Data .37
Development Risks 38
Company Expertise 38
Competition within the Market-place ....39
Competitor Ratio Analysis ....40
Forecast ...40
Clinical Trial Results ..41
BAVITUXIMAB .. 43
Mode of Action 43
Current Status .43
Proof of Concept/Clinical Data .43
Development Risks 44
Company Expertise 44
Competition within the Market-place ....44
Competitor Ratio Analysis ....45
BIBW 2992 ... 46
Mode of Action 46
Current Status .46
Proof of Concept/Clinical Data .47
Development Risks 47
Company Expertise 47
Competition within the Market-place ....48
Competitor Ratio Analysis ....48
Forecast ...48
Clinical Trial Results ..49
BOSUTINIB . 51
Mode of Action 51
Current Status .51
Clinical Trial Results ....51
CIXUTUMUMAB 52
Mode of Action 52
Current Status .52
Proof of Concept/Clinical Data .52
Development Risks 53
Company Expertise 53
Competition within the Market-place ....53
Competitor Ratio Analysis ....53
E75 GM-CSF ADJUVANT VACCINE ..... 54
Mode of Action 54
Current Status .54
Proof of Concept/Clinical Data .54
Development Risks 54
Company Expertise 55
Competition Within the Market-place ...55
Competitor Ratio Analysis ....56
Forecast ...56
FIGITUMUMAB .. 57
Mode of Action 57
Current Status .57
Proof of Concept ...57
Development Risks 58
Company Expertise 58
Competition within the Market-place ....58
Competitor Ratio Analysis ....59
GIMATECAN ..... 61
Mode of Action 61
Proof of Concept/Clinical Data .61
LINIFANIB ... 62
Mode of Action 62
Current Status .62
Proof of Concept/Clinical Data .62
Development Risks 63
Company Expertise 63
Competition within the Market-place ....63
Competitor Ratio Analysis ....64
MOTESANIB DIPHOSPHATE ... 65
Mode of Action 65
Current Status .65
Proof of Concept/Clinical Data .65
Development Risks 65
Company Expertise 65
Competition within the Market-place ....66
Competitor Ratio Analysis ....67
Forecast ...67
NOV-002 70
Mode of Action 70
Current Status .70
Proof of Concept ...70
Development Risks 71
Company Expertise 71
Competition within the Market-place ....71
Competitor Ratio Analysis ....72
Forecast ...72
OLAPARIB .. 73
Mode of Action 73
Current Status .73
Proof of Concept/Clinical Data .73
Development Risks 74
Company Expertise 74
Competition within the Market-place ....75
Competitor Ratio Analysis ....75
RETASPIMYCIN 76
Mode of Action 76
Current Status .76
Proof of Concept/Clinical Data .76
Development Risks 76
Company Expertise 77
Competition within the Market-place ....77
Competitor Ratio Analysis ....78
RETASPIMYCIN 79
Mode of Action 79
Current Status .79
Proof of Concept/Clinical Data .79
Development Risks 79
Company Expertise 80
Competition within the Market-place ....80
Competitor Ratio Analysis ....81
SORAFENIB 82
Mode of Action 82
Current Status .82
Proof of Concept/Clinical Data .84
Development Risks 84
Company Expertise 85
Competition within the Market-place ....85
Data Exclusivity .....86
Patent Expiry ...86
Competitor Ratio Analysis ....87
Forecast ...87
SU14813 90
Mode of Action 90
Current Status .90
TAS-108 . 91
Mode of Action 91
Current Status .91
TSU-68 .. 92
Mode of Action 92
Current Status .92
Proof of Concept/Clinical Data .92
Development Risks 92
Company Expertise 92
Competition within the Market-place ....92
Competitor Ratio Analysis ....93
VANDETANIB .... 94
Mode of Action 94
Current Status .94
Proof of Concept/Clinical Data .94
Development Risks 94
Company Expertise 94
Competition Within the Market-place ...95
Competitor Ratio Analysis ....95
Forecast ...95
Clinical Trial Results ..96
YM155 ... 97
Current Status .97
Proof of Concept/Clinical Data .97
CANFOSFAMIDE .... 98
Mode of Action 98
Current Status .98
Proof of Concept/Clinical Data .98
Development Risks 99
Company Expertise 99
Competition within the Market-place ....99
Competitor Ratio Analysis ..100
PAZOPANIB .... 101
Mode of Action ....101
Current Status .....101
Proof of Concept/Clinical Data .....101
Development Risks ....102
Company Expertise ....102
Competition within the Market-place ..103
Data Exclusivity ...103
Patent Expiry .103
Competitor Ratio Analysis ..104
Forecast .104
Clinical Trial Results 106
BSI-201 107
Mode of Action ....107
Current Status .....107
Proof of Concept/Clinical Data .....108
Development Risks ....108
Company Expertise ....108
Competition within the Market-place ..108
Competitor Ratio Analysis ..109
Clinical Trial Results 109
ERBULIN ... 110
Clinical Trial Results 110
EVEROLIMUS . 111
Mode of Action ....111
Current Status .....112
Proof of Concept/Clinical Data .....113
Development Risks ....115
Company Expertise ....115
Competition within the Market-place ..116
Competitor Ratio Analysis ..117
Forecast .117
NERATINIB 122
Mode of Action ....122
Current Status .....122
Proof of Concept/Clinical Data .....122
Development Risks ....122
Company Expertise ....122
Clinical Trial Results 123
PERTUZUMAB 124
Mode of Action ....124
Current Status .....124
Proof of Concept/Clinical Data .....124
Development Risks ....125
Company Expertise ....125
Competition within the Market-place ..125
Competitor Ratio Analysis ..126
Forecast .126
Clinical Trial Results 127
RAMUCIRUMAB .... 129
Mode of Action ....129
Current Status .....129
Proof of Concept/Clinical Data .....129
Development Risks ....129
Company Expertise ....129
Competition within the Market-place ..130
Competitor Ratio Analysis ..130
Forecast .130
TRABECTIDIN . 132
Mode of Action ....132
Current Status .....132
Further Development .132
VADIMEZAN .... 135
Mode of Action ....135
Current Status .....135
Proof of Concept/Clinical Data .....136
Development Risks ....136
Company Expertise ....136
Competition Within the Market-place .137
Competitor Ratio Analysis ..137
Forecast .137
Clinical Trial Results 138
ANASTROZOLE .... 140
Mode of Action ....140
Current Status .....140
Proof of Concept/Clinical Data .....141
Development Risks ....142
Company Expertise ....142
Competition Within the Market-place .143
Data Exclusivity ...143
Patent Expiry .143
Generic Competition 144
Competitor Ratio Analysis ..144
Forecast .144
Clinical Trial Results 145
BEVACIZUMAB ..... 148
Mode of Action ....148
Current Status .....148
Proof of Concept/Clinical Data .....151
Development Risks ....154
Company Expertise ....155
Competition within the Market-place ..156
Competitor Ratio Analysis ..157
Forecast .158
CAPECITABINE .... 165
Mode of Action ....165
Current Status .....165
Proof of Concept/Clinical Data .....167
Development Risks ....169
Company Expertise ....169
Competition within the Market-place ..169
Patent Expiry .170
Competitor Ratio Analysis ..170
Forecast .170
Clinical Trial Results 173
DOCETAXEL ... 176
Mode of Action ....176
Current Status .....176
Proof of Concept .179
Development Risks ....184
Company Expertise ....185
Competition within the Market-place ..185
Competitor Ratio Analysis ..186
Forecast .187
DOXIFLURIDINE ... 190
Mode of Action ....190
Current Status .....190
DOXORUBICIN 191
Clinical Trial Results 191
EXEMESTANE 192
Mode of Action ....192
Current Status .....192
Proof of Concept/Clinical Data .....192
Development Risks ....193
Company Expertise ....193
Competition within the Market-place ..193
Data Exclusivity ...193
Patent Expiry .194
Competitor Ratio Analysis ..194
Forecast .194
FULVESTRANT ..... 196
Mode of Action ....196
Sales .196
Current Status .....196
Proof of concept/clinical data .196
Development Risks ....197
Company Expertise ....198
Competition within the Market-place ..198
Competitor Ratio Analysis ..198
Forecast .199
GEMCITABINE 200
Current Status .....200
Proof of Concept/Clinical Data .....201
Development Risks ....202
Company Expertise ....202
Competition within the Market-place ..203
Patent Expiry .203
Generic Competition 203
Competitor Ratio Analysis ..205
Forecast .205
Clinical Trial Results 206
Metastatic Breast Cancer .. 206
Pancreatic Cancer. 207
GOSERELIN .... 209
Mode of Action ....209
Sales .209
Current Status .....209
Proof of Concept .211
Development Risks ....211
Company Expertise ....212
Competition Within the Market-place .212
Competitor Ratio Analysis ..213
Forecast .213
IXABEPILONE . 215
Mode of Action ....215
Current Status .....215
Proof of Concept/Clinical Data .....215
Development Risks ....216
Company Expertise ....216
Competition within the Market-place ..217
Competitor Ratio Analysis ..217
Forecast .217
Clinical Trial Results 218
LAPATINIB 220
Mode of Action ....220
Current Status .....220
Proof of Concept/Clinical Data .....221
Development Risks ....222
Company Expertise ....223
Competition within the Market-place ..223
Data Exclusivity ...223
Patent Expiry .224
Competitor Ratio Analysis ..224
Forecast .224
Clinical Trial Results 226
LETROZOLE ... 227
Mode of Action ....227
Current Status .....227
Proof of Concept .228
Development Risks ....228
Company Expertise ....228
Competition within the Market-place ..229
Patent Expiry .229
Generic Competition 229
Competitor Ratio Analysis ..229
Forecast .229
Clinical Trial Results 230
PACLITAXEL ALBUMIN-BOUND PARTICLES .... 232
Mode of Action ....232
Current Status .....232
Proof of Concept .233
Development Risks ....233
Company Expertise ....234
Competition Within the Market-place .234
Data Exclusivity .... 235
Patent Expiry .. 235
Generic Competition 235
Competitor Ratio Analysis ..235
Forecast .236
Clinical Trial Results 236
PACLITAXEL ... 238
RALOXIFENE .. 239
Mode of Action ....239
Current Status .....239
Proof of Concept .240
Development Risks ....241
Company Expertise ....241
Competition within the Market-place ..241
Data Exclusivity ...242
Patent Expiry .242
Generic Competition ..242
Competitor Ratio Analysis ..243
Forecast .243
Clinical Trial Results 244
TAMOXIFEN .... 246
Mode of Action ....246
Current Status .....246
Proof of Concept/Clinical Data .....246
Development Risks ....247
Company Expertise ....247
Competition within the Market-place ..247
Data Exclusivity ...247
Generic Competition 248
Competitor Ratio Analysis ..248
Forecast .248
TOREMIFENE .. 250
Mode of Action ....250
Current Status .....250
Proof of Concept/Clinical Data .....250
Development Risks ....251
Company Expertise ....251
Competition within the Market-place ..252
Competitor Ratio Analysis ..252
TRASTUZUMAB .... 253
Mode of Action ....253
Current Status .....253
Proof of Concept/Clinical Data .....255
Development Risks ....257
Company Expertise ....257
Competition within the Market-place ..258
Patent Expiry .259
Competitor Ratio Analysis ..259
Forecast .259
Clinical Trial Results 260
ABT-751 .... 263
Mode of Action ....263
Current Status .....263
ARZOXIFENE .. 264
Mode of Action ....264
Current Status .....264
Proof of Concept/Clinical Data .....264
ENZASTAURIN 265
Mode of Action ....265
Current Status .....265
Proof of Concept/Clinical Data .....265
Development Risks ....265
Company Expertise ....266
Competition within the Market-place ..266
Competitor Ratio Analysis ..266
Forecast .267
Clinical Trial Results 267
SAGOPILONE . 268
Mode of Action ....268
Current Status .....268
Proof of Concept/Clinical Data .....268
Company Expertise ....268
Competition within the Market-place ..269
Competitor Ratio Analysis ..269
PD-325901 . 270
Mode of Action ....270
Current Status .....270
Proof of Concept/Clinical Data .....270
SARACATINIB 271
Mode of Action ....271
Current Status .....271
SUNITINIB MALATE ... 272
Mode of Action ....272
Current Status .....272
Proof of Concept/Clinical Data .....273
Development Risks ....274
Company Expertise ....275
Competition within the Market-place ..275
Data Exclusivity ...276
Patent Expiry .276
Generic Competition 276
Competitor Ratio Analysis ..277
Forecast .277
Clinical Trial Results 280
TANESPIMYCIN .... 282
Mode of Action ....282
Current Status .....282
Proof of Concept/Clinical Data .....282
Development Risks ....282
Company Expertise ....283
Competition within the Market-place ..283
Competitor Ratio Analysis ..283
METHODOLOGY ... 284
